← Human Trials & Peer-Reviewed Studies
Supraphysiological growth hormone: less fat, more extracellular fluid but uncertain effects on muscles in healthy, active young adults.
Plain-language guide to PMID 15807876 (2005): double-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 15 men.
Key Facts
- PMID
- 15807876
- Journal
- Clinical endocrinology
- Year
- 2005
- Study type
- Randomized Controlled Trial
- Authors
- Ehrnborg C et al. (5 authors)
- DOI
- 10.1111/j.1365-2265.2005.02240.x
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.
Who Took Part
The study group was 15 men.
PubMed indexes the participants as teenagers and adults, both men and women.
Thirty healthy, physically active volunteers (15 men and 15 women), mean age 25.9 years (range 18-35), participated in this study, designed as a randomized, double-blind, placebo-controlled, parallel study with three groups (n = 10: five men and five women in each group).
How the Study Was Run
In design terms this was a randomized, double-blind, placebo-controlled and parallel-group study.
The men were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.
Neither the men nor the staff measuring them knew who was on Exogenous HGH, sermorelin & older GHRPs (why they're passed over), so expectations could not easily colour the readings.
Some men received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.
The Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group ran side by side rather than switching.
What Was Measured
PubMed files the paper under topics including Absorptiometry, Photon, Adipose Tissue, Body Composition, Electric Impedance, Extracellular Fluid, Growth Hormone and Insulin-Like Growth Factor I.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 15 men.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2005 (Clinical endocrinology), a journal based in England.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.